Zurn Elkay Water Q2 sales beat estimates
Reuters2026/07/28 20:26
Overview
US water management firm's Q2 net sales rose 10%, beating analyst expectations
Adjusted EPS for Q2 increased to $0.50 from $0.42 a year ago
Company repurchased $50 mln in shares and completed Intellihot acquisition
Outlook
Zurn Elkay expects Q3 core sales growth of 6% to 7% and adjusted EBITDA margin near 28%
Company sees full-year 2026 adjusted EBITDA between $503 mln and $513 mln
Zurn Elkay expects full-year free cash flow of at least $350 mln, excluding tariff refunds
Result Drivers
CORE SALES GROWTH - 10% increase in core sales, with growth across all product categories, drove higher revenue
PRICE REALIZATION AND PRODUCTIVITY - Margin expansion attributed to price realization and productivity initiatives under the Zurn Elkay Business System
Company press release: ID:nBw2C6nGma
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Sales |
Beat |
$491 mln |
$483.09 mln (9 Analysts) |
Q2 Net Income |
|
$113.30 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the construction supplies fixtures peer group is "buy"
Wall Street's median 12-month price target for Zurn Elkay Water Solutions Corp is $56.00, about 14.8% above its July 27 closing price of $48.77
The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 26 three months ago
Reuters Recommended Reads
July 28 - Xylem raises annual profit forecast as AI growth lifts demand for water-treatment equipment
July 28 - Pentair falls as pool equipment destocking hits sales; to buy Taco Group for $1.4 billion
July 28 - Ecolab raises annual profit forecast on pricing, high-tech demand
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin's Weirdest Trader Yet? Fly Brain Makes a Profit
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street -- WSJ
NASDAQ TRADE HALT CONTINUES <MAMK.O> REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM